# US 2019/0314344 A9 · Methods of treating inflammatory bowel disease with amd3100 and tacrolimus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314344 A9
- Document ID: US20190314344A9
- Status: Published application
- Kind: A9
- Application number: 14/814,988
- Filed: 2015-07-31
- Published: 2019-10-17
- Earliest claimed: 2009-12-11
- Assignees: MedRegen, LLC
- Applicants: MedRegen, LLC
- Inventors: Zhaoli Sun; Xuhang Li
- Web page: https://patentgrep.com/patent/US20190314344A9

## CPC

- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 9/2004: {Excipients; Inactive ingredients}
- A61K 9/4841: {Filling excipients; Inactive ingredients}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/365: Lactones
- A61K 31/395: having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K 31/4427: containing further heterocyclic ring systems
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 38/13: Cyclosporins
- A61K 38/18: Growth factors; Growth regulators
- A61K 38/19: Cytokines; Lymphokines; Interferons
- A61K 38/193: {Colony stimulating factors [CSF]}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the field of inflammatory bowel disease. In one aspect, the present invention provides methods for treating inflammatory bowel disease in a patient comprising administering to the patient a therapeutically effective amount of a stem cell mobilizer and an immunosuppressive agent. In particular embodiments, the present invention provides a method for treating inflammatory bowel disease in a patient comprising administering to the patient a therapeutically effective amount of an agent that mobilizes CD34+ and/or CD133+ stem cells and a low dose of an immunosuppressive agent.

## Claims

### Claim 1

A method of treating inflammatory bowel disease in a patient comprising administering to the patient a therapeutically effective amount of a stem cell mobilizer and an immunosuppressive agent.

### Claim 2 (depends on 1)

The method of claim 1, wherein the stem cell mobilizer is selected from the group consisting of AMD3100, AMD3465, TG-0054, G-CSF, GM-CSF, SDF-1, and SCF.

### Claim 3 (depends on 1)

The method of claim 1, wherein the stem cell mobilizer is a CXCR4 antagonist.

### Claim 4 (depends on 3)

The method of claim 3, wherein the stem cell mobilizer is AMD3100.

### Claim 5 (depends on 1)

The method of claim 1, wherein the immunosuppressive agent is selected from the group consisting of Tacrolimus, cyclosporine, Orthoclone OKT3, mycophenolate, and sirolimus.

### Claim 6 (depends on 5)

The method of claim 5, wherein the immunosuppressive agent is Tacrolimus.

### Claim 7 (depends on 1)

The method of claim 1, wherein the immunosuppressive agent is administered in a low dose amount.

### Claim 8 (depends on 1)

The method of claim 1, wherein the stem cell mobilizer is AMD3100 and the immunosuppressive agent is Tacrolimus.

### Claim 9

A method of treating inflammatory bowel disease in a patient comprising administering to the patient a therapeutically effective amount of an agent that mobilizes CD34+ and/or CD133+ stem cells and a low dose of an immunosuppressive agent.

### Claim 10 (depends on 9)

The method of claim 9, wherein the agent that mobilizes CD34+ and/or CD133+ stem cells is AMD3100 and the immunosuppressive agent is Tacrolimus.
